TD Cowen initiated coverage of Viridian Therapeutics (VRDN) with a Buy rating and no price target The company’s lead asset veligrotug is an anti-IGF-1R therapy in development for thyroid eye disease designed to reduce IV delivery burden, the analyst tells investors in a research note. The firm says the initial Phase III data in active TED patients were strong with the chronic data set for December. A subcutaneous program is also in Phase III development, adds RD, which believes the shares as undervalued for Viridian’s TED opportunity alone.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs
- Viridian Therapeutics price target raised to $34 from $27 at H.C. Wainwright
- Viridian Therapeutics Reports Increased Cash Reserves Amid Losses
- Viridian Therapeutics Advances in Biotech Innovations
- Viridian Therapeutics reports Q3 EPS ($1.15), consensus ($1.06)